The long-term perspective on the pharmaceutical heavyweight appears interesting!
The valuation of Pfizer appears attractive for investors at this point!
In the last three years, the dividend payout per share has been increased each year. Another increase could positively affect the dividend yield!
Reading Time: 1 minute
Pfizer (PFE) could be interesting for long-term investors due to a combination of an attractive dividend, a strategic realignment after the COVID boom, and promising developments in the pipeline, even though the company is currently facing challenges. Following the peak of the COVID-19 pandemic, sales of COVID products (Comirnaty and Paxlovid) have significantly decreased, leading to a noticeable decline in overall revenues for the company. Pfizer responded with a radical restructuring and a focus on long-term, sustainable growth. A key focus is...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
